Kiora EVP Lane Keith reports no share holdings

Kiora Pharmaceuticals filed a Form 3 for its EVP, Clinical and Regulatory, with no transactions or holdings reported.

Rhea-AI Filing Summary

Kiora Pharmaceuticals Inc (KPRX) reported an initial statement of beneficial ownership on Form 3 for Lane Keith J., identified as "EVP, Clinical and Regulatory." The filing reports no equity transactions or derivative positions and lists no specific holdings for this reporting person as of the filing date.

Key Figures

Reported buy transactions: 0 transactions Reported sell transactions: 0 transactions Reported derivative transactions: 0 transactions +1 more

4 metrics

Reported buy transactions 0 transactions Transaction summary for this Form 3

Reported sell transactions 0 transactions Transaction summary for this Form 3

Reported derivative transactions 0 transactions Derivative transaction count in transaction summary

Holding entries 0 entries Number of holdings rows reported in the Form 3

Key Terms

Initial statement of beneficial ownership, Form 3, Power of Attorney

3 terms

Initial statement of beneficial ownership regulatory

"reported an initial statement of beneficial ownership on Form 3"

An initial statement of beneficial ownership is the first regulatory filing an insider or large investor submits to disclose the amount of a company's stock they control or benefit from. It matters to investors because it reveals who has significant influence over a company—like showing who’s holding the cards—and helps track potential conflicts of interest, insider motives, and future buying or selling that can move the stock price.

Form 3 regulatory

"reported an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Power of Attorney regulatory

"Exhibit 24.1 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kiora Pharmaceuticals' (KPRX) latest Form 3 filing report?

It reports an initial statement of beneficial ownership for Lane Keith J., EVP, Clinical and Regulatory, with no transactions, derivative positions, or specific holdings listed in the filing.

Who is the reporting person in KPRX’s Form 3 filing?

The reporting person is Lane Keith J., identified in the filing as "EVP, Clinical and Regulatory" of Kiora Pharmaceuticals Inc.

Does the KPRX Form 3 show any share transactions by the reporting person?

No. The Form 3’s transaction summary shows no reported purchases, sales, gifts, exercises, or other transactions by the reporting person.

Are any derivative securities reported in the KPRX Form 3?

No. The filing’s derivative summary is empty, indicating no options, warrants, or other derivative securities are reported for the reporting person in this Form 3.

What exhibit is referenced in Kiora Pharmaceuticals’ Form 3?

The remarks section lists an exhibit: Exhibit 24.1 - Power of Attorney, which typically authorizes someone to sign SEC forms on behalf of the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:28 PM Accepted by SEC EDGAR 09/17/2026 - 09:27 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lane Keith J.

(Last) (First) (Middle)

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2026

3. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			EVP, Clinical and Regulatory

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Melissa Tosca, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)